Nivolumab and Ipilimumab in Treating Patients With Rare Tumors
Lay Description
This repository is a multi-center, outcomes study designed to collect data on the demographics, presentation, diagnosis, treatment, cost of associated care, quality of life, and outcomes of subjects utilizing Caris Molecular Intelligence® (CMI) Services for the treatment of cancer. Prior to enrolling a subject, the subject¿s physician will have made the independent decision whether or not to utilize the drug associations provided by CMI and made clinical treatment choices as appropriate. Thus, data captured and reported provides a ¿real world¿ perspective on diagnosis, treatment, cost, and outcomes.
Category
- Multiple Sites
- IRB Number
- 20170353HU
- NCT Number
- ct.gov registration not required
- Open to Enrollment
- Yes
Eligibility
- Eligible Ages
- 18 Years -
- Eligible Genders
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
Exclusion Criteria
Study Design
Study Contact
Regulatory Point of Contact
Frances Crawford
210-450-5037
crawfordf1@uthscsa.edu
Regulatory Point of Contact
Myrna Montenegro
210-450-5954
montenegro@uthscsa.edu
Regulatory Point of Contact
Kathleen Rodriguez
210-450-1365
rodriguezk3@uthscsa.edu
Regulatory Point of Contact
Benjamin Schleif
210-450-1366
schleifb@uthscsa.edu
Regulatory Point of Contact
Morgan Seekatz
210-450-1133
seekatz@uthscsa.edu
Principal Investigator
Sukeshi Arora